Brazil · Delayed Price · Currency is BRL Ser Educacional Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw robust growth in revenue, net income, and cash generation, driven by on-campus undergrad expansion and higher average ticket. Net debt fell over 35%, and the company resumed dividends while planning further organic and medical seat expansion.
Fiscal Year 2025
-
Double-digit growth in hybrid education and a 22% rise in Adjusted EBITDA marked a strong year, with net income swinging to BRL 74.6 million and leverage at historic lows. Focus shifts to organic expansion, healthcare, and consistent dividends in 2026.
-
Q3 2025 saw robust financial and operational gains, with cash generation more than doubling year-over-year and leverage dropping over 20%. Student base and average ticket grew, especially in healthcare, while cost controls and efficiency measures drove margin and cash flow improvements.
-
Q2 2025 saw double-digit enrollment growth, strong EBITDA and net margin expansion, and a 26% higher net profit versus 2024. Medical programs and hybrid education drove results, while debt and leverage were significantly reduced.
-
Strong year-over-year growth in student intake and revenue, record Adjusted EBITDA, and improved cash generation were driven by expansion in health and hybrid education segments. Financial leverage declined, enabling dividend resumption and supporting a disciplined growth outlook.
Fiscal Year 2024
-
Double-digit adjusted EBITDA growth and over 200% increase in net operating cash enabled a 9% net debt reduction and dividend resumption. Health and medical courses drove student base and margin expansion, while operational optimization improved cash flow and leverage.
-
Operational optimization drove revenue and margin growth, with adjusted net income turning positive and leverage falling below 1.8x. Enrollment and average ticket rose, especially in health courses, while new medical seats and the Ser Solidarity Program set the stage for future growth.
-
Strong student intake and operational synergies drove margin and cash flow improvements, with medical course expansion supporting future growth. Net Debt/EBITDA fell to 1.93x, and CapEx will normalize in H2. Regulatory and market risks remain.